Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The COVID-19 outbreak requires a rapid re-shaping of the entire organization of the rehabilitation services. This includes the design and planning of appropriate rehabilitation settings, intervention and logistics for organizing space for patients. The aims of this study are: (a) to evaluate the feasibility of the bedside use of a novel rehabilitation device for upper limb in patients with stroke; (b) to evaluate the motor and cognitive outcomes of the treatment; (c) to validate the instrumental outcomes provided by the device.
Description: It is a tool for measuring the usability
Measure: System Usability Scale (SUS) Time: After 30 rehabilitation sessionsDescription: It is a tool for measuring the acceptability.
Measure: Technology Acceptance Model (TAM) Time: After 30 rehabilitation sessionsDescription: It is a tool for measuring the satisfaction.
Measure: Likert Scale Time: After 30 rehabilitation sessionsDescription: The Fugl-Meyer Assessment is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, sensation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research to determine disease severity, describe motor recovery, and to plan and assess treatment.
Measure: Fugl-Meyer Assessment for upper extremity (FMA-UE) Time: At baseline; after 30 rehabilitation sessionsDescription: It is a clinical instrument for characterizing the strength of the paretic upper extremity following stroke.
Measure: Motricity Index for the upper extremity (MI-UE) Time: At baseline; after 30 rehabilitation sessionsDescription: It is a clinical instrument for characterizing upper limb spasticity. Shoulder, elbow and wrist spasticity will be assessed.
Measure: Modified Ashworth Scale (MAS) Time: At baseline; after 30 session rehabilitation sessionsDescription: It is a unidimensional measure of pain intensity in adults.
Measure: Numeric Pain Rating Scale (NPRS) Time: At baseline; after 30 rehabilitation sessionsDescription: It is a measure of independence in activities of daily living.
Measure: Modified Barthel Index (mBI) Time: At baseline; after 30 rehabilitation sessionsDescription: It is a widely used screening assessment for detecting cognitive impairment.
Measure: Montreal Cognitive Assessment (MoCA) Time: At baseline; after 30 rehabilitation sessionsDescription: The kinematics of the end-effector of the robot will be acquired during point-to-point tasks.
Measure: Kinematic parameters Time: At baseline (twice, one day apart); after 10 rehabilitation sessions; after 20 rehabilitation sessions; after 30 rehabilitation sessionsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports